

Health Sciences Fund (PRHSX)

As of April 30, 2026



T. Rowe Price

Portfolio Management	Managed Since	Joined Firm
Ziad Bakri	2016	2011
Jeff Holford	2026	2018

Effective 1 April 2026, Jeff Holford, assumed co-portfolio management responsibility for the Fund.

Investment Objective

The fund seeks long-term capital appreciation.

General Information

CUSIP	741480107
Inception Date	December 29, 1995
Benchmark	Russell 3000 Health Care Index
Expense Information (as of the most recent Prospectus)	0.83%

Market Commentary

U.S. equity markets rebounded in April, recovering losses sustained in March as the geopolitical backdrop shifted materially following a series of ceasefire agreements in the Middle East. The initial weeks of the month were marked by elevated uncertainty as investors weighed the durability of a conditional U.S.-Iran ceasefire announced in early April against continued disruptions in energy markets and shipping routes. As the month progressed and additional diplomatic milestones were reached, equities rallied with sustained momentum, and multiple major indexes recorded new all-time highs.

The Russell 3000 Health Care Index was flat in April and underperformed the broad equity market, as represented by the S&P 500 Index. Subsector performance within the health care index was mixed. While the services segment posted double-digit gains, products and devices, pharmaceuticals, life sciences, and biotechnology all lost ground.

Performance (%) (NAV, total return Performance > 1yr is Annualized)

	1m	3m	YTD	1yr	3yrs	5yrs	10yrs	15yrs
Health Sciences Fund (PRHSX)	1.60	-3.80	-4.74	12.28	5.17	2.27	9.84	13.13
Lipper Health/Biotechnology Funds Index (LPH)	0.83	-4.51	-4.90	16.24	6.52	1.64	9.01	11.63
Russell 3000 Health Care Index (RUS3H)	-0.04	-4.78	-4.91	8.61	5.12	3.95	9.46	11.76

The 1-, 5-, and 10-year annualized returns as of 2026-03-31 were 10.42%, 2.93% and 9.85% for the Fund.

Past performance is not a guarantee or a reliable indicator of future results. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. To obtain the most recent month-end performance, visit [troweprice.com](https://www.troweprice.com).

The Fund's total return figures reflect the reinvestment of dividends and capital gains, if any.

The fund(s) may have other share classes available that offer different investment minimums and fees. See the prospectus for details.

Risks: Health sciences companies: A fund that focuses its investments in specific industries or sectors is more susceptible to adverse developments affecting those industries and sectors than a more broadly diversified fund. **Large- and mid-cap stocks:** Securities issued by large- and mid-cap companies tend to be less volatile than securities issued by small-cap companies. However, large-cap companies may not be able to attain the high growth rates of successful small-cap companies, especially during strong economic periods, and may be unable to respond as quickly to competitive challenges. See the prospectus for more detail on the fund's principal risks.


Risk Return Characteristics (Five Years ended April 30, 2026)

	Annualized Std. Deviation (%)	Alpha (%)	Beta	R-Squared	Information Ratio	Sharpe Ratio	Tracking Error (%)
Health Sciences Fund	15.40	-1.48	1.00	0.89	-0.32	-0.08	5.20
Russell 3000 Health Care Index	14.51	0.00	1.00	1.00	0.00	0.03	0.00
Health Sciences Fund	15.40	0.60	0.97	0.94	0.16	-0.08	3.94
LPR Health/Biotech Ix	15.34	0.00	1.00	1.00	0.00	-0.12	0.00

Past performance is not a guarantee or a reliable indicator of future results.

Figures are calculated using monthly data and are net of fees.

Sector Attribution Data: Fund vs Russell 3000 Health Care Index (12 Months ended April 30, 2026) (%)



	Total	Biotechnology	Products & Devices	Services	Consumer Nondurables	Miscellaneous	Life Sciences	Pharmaceuticals
Over (Under) Weight	0.00	17.31	-8.50	-1.87	0.00	-0.04	-0.50	-7.49
Fund Performance	13.09	40.66	-16.84	0.13	85.70	17.51	-3.36	6.55
Index Performance	8.63	31.26	-14.75	-1.64	49.37	24.31	4.51	19.01
Sector Allocation Effect	4.82	4.54	2.08	-0.16	0.00	0.00	-0.10	-1.66
Stock Selection Effect	-0.36	3.15	-0.76	0.29	0.08	0.00	-0.67	-2.45
Total Effect	4.46	7.69	1.32	0.13	0.09	0.00	-0.76	-4.11

Past performance is not a guarantee or a reliable indicator of future results. Analysis represents the total performance of the portfolio as calculated by the FactSet attribution model and is inclusive of other assets. Non-equity positions are excluded from structure shown. Returns will not match official T. Rowe Price performance because FactSet uses different exchange rate sources and does not capture intra-day trading. Performance for each security is obtained in the local currency and, if necessary, is converted to USD using an exchange rate determined by an independent third party. Figures are shown with gross dividends reinvested.

Sources: Financial data and analytics provider FactSet. Copyright 2026 FactSet. All Rights Reserved. Analysis by T. Rowe Price. Figures are shown gross of fees. Returns would be lower as a result of the deduction of such fees.

Top 10 Issuers (%)	Industry	Fund
Eli Lilly and Co	Major Pharmaceuticals	11.8
Johnson & Johnson	Major Pharmaceuticals	5.9
UnitedHealth Group	Payors	5.6
AbbVie	Major Pharmaceuticals	5.0
Thermo Fisher Scientific	Life Sciences	3.5
Merck	Major Pharmaceuticals	3.3
Intuitive Surgical	Implants	3.2
Gilead Sciences	Major Biotechnology	2.4
Vertex Pharmaceuticals	Major Biotechnology	2.3
Stryker	Implants	2.1

Comprising 45.1% of total net assets.

Portfolio Characteristics	Fund	RUS3H	LPH
Number of Issuers	209	491	495
Investment Weighted Average Market Cap (mm)	\$240,537	\$266,415	\$149,188
Price to Earnings (12 Months Forward) ⁽¹⁾⁽²⁾⁽³⁾	12.6X	16.9X	10.9X
Price to Book (trailing) ⁽²⁾	6.0X	5.5X	5.9X
Projected Earnings Growth Rate (3-5 Years) ⁽¹⁾⁽²⁾⁽³⁾	6.8%	7.6%	6.8%
Return on Equity (Last 12 Months excl. charges) ⁽²⁾	18.3%	34.7%	10.0%
Top 20 Issuers as Percent of Total	58.1%	69.6%	48.3%
Total Assets (all share classes)	\$10,924,061,471	N/A	N/A
Percent of Portfolio in Cash	1.1%	N/A	N/A

⁽¹⁾Source: Financial data and analytics provider FactSet. Copyright 2026 FactSet. All Rights Reserved.

⁽²⁾Statistics are based on Investment Weighted Average.

⁽³⁾These statistics are based on the Fund's underlying holdings and are not a projection of future portfolio performance. Actual results may vary.

Sector Diversification (%)	Fund	RUS3H
Biotechnology	38.0	21.0
Pharmaceuticals	29.8	37.3
Services	14.9	16.7
Products & Devices	9.3	17.8
Life Sciences	6.7	7.2
Misc.	0.2	0.0
Consumer Nondurables	0.0	0.0

Geographical

Diversification (%)	Fund	Fund vs RUS3H
United States	93.3	-6.5
Netherlands	1.4	1.4
United Kingdom	1.3	1.3
China	0.8	0.8
Denmark	0.8	0.8
Japan	0.6	0.6
France	0.5	0.5
Switzerland	0.1	0.1
Germany	0.1	-0.1
Israel	0.0	0.0

Additional Disclosures & Definitions

Consider the investment objectives, risks, and charges and expenses carefully before investing. For a prospectus or, if available, a summary prospectus containing this and other information, call 1-800-638-7780 or visit troweprice.com. Read it carefully.

Visit Troweprice.com/glossary for a glossary of financial terminology.

FTSE/Russell, and Lipper do not accept any liability for any errors or omissions in the indexes or data, and hereby expressly disclaim all warranties of originality, accuracy, completeness, timeliness, merchantability, and fitness for a particular purpose. No party may rely on any indexes or data contained in this communication. Visit Troweprice.com/marketdata for additional legal notices & disclaimers.

Portfolio holdings in this report are presented gross of any non-reclaimable withholding tax. Any non-reclaimable withholding tax is included in position market values. Portfolio diversification data is calculated net of any non-reclaimable withholding tax. Any non-reclaimable tax withheld is not reflected in category market values.

Fund Assets, holdings-based analytics (excluding portfolio turnover), and portfolio attribution are calculated using T. Rowe Price's internal Investment Book of Records (IBOR). Due to timing and accounting methodology differences, IBOR data may differ from the Accounting Book of Records (ABOR) data provided by the Fund's accountant.

Unless otherwise noted, index returns are shown with gross dividends reinvested.

T. Rowe Price uses a custom structure for sector and industry reporting for this product.

Diversification exhibits may not add to 100% due to exclusion or inclusion of cash.

Certain numbers in this report may not equal stated totals due to rounding. Unless otherwise stated, data is as of the report date.

Unless indicated otherwise the source of all data is T. Rowe Price.

This material should not be deemed a recommendation to buy or sell any of the securities mentioned.

This material has been prepared for informational purposes only. The views and opinions stated in this commentary are those of the portfolio managers listed as of the date indicated. These views and opinions are subject to change based on market or other conditions and may differ from those of other T. Rowe Price associates. Actual market and investment results may differ materially from expectations.

© 2026 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, the Bighorn Sheep design, and related indicators (see troweprice.com/ip) are trademarks of T. Rowe Price Group, Inc. All other trademarks are the property of their respective owners. Use does not imply endorsement, sponsorship, or affiliation of T. Rowe Price with any of the trademark owners.

T. Rowe Price Investment Services, Inc., Distributor.

201705-152331 202605-5451577